Coherus BioSciences Inc at JPMorgan Healthcare Conference Transcript
&-
Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Coherus this morning. From the company, we have Denny Lanfear, President and CEO, who is going to make some opening remarks, and we're going to jump into a Q&A session from there with the broader management team. So that happened to you, Denny, and over to you.
Thank you.
Chris, and thank you once again for having us at the conference this year. Let me first, of course, apprise you of the forward-looking statements, which will address issues with the revenue projections, product development, time lines, the various assets, the future of those products and so on. And then we, of course, refer you to the Company's regulatory filings. So today, what I'd like to do is, first of all, give you a flyby summary of the Company. We've made substantial progress on our strategy of moving to an oncology company. We are revenue stage
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
